Abstract
Blockade of PD-1/PD-L1 interactions using PD-1/PD-L1 pathway modulators has shown unprecedented clinical efficacy in various cancer models. Current PD-1/PD-L1 modulators approved by FDA are exclusively dominated by therapeutic antibodies. Nevertheless, therapeutic antibodies also exhibit several disadvantages such as low tumor penetration, difficulty in crossing physiological barriers, lacking oral bioavailability, high manufacturing costs, inaccessible to intracellular targets, immunogenicity, immune-related adverse events (irAEs). Modulation of PD-1/PD-L1 pathway using small molecules may be an alternative approach to mobilize immune system to fight against cancers. In this review, we focus on summarizing the recently disclosed chemical structures and preliminary structure-activity relationships (SARs) of small molecules as PD-1/PD-L1 modulators for cancer immunotherapy.
Keywords: Immune checkpoint modulators, sulfonamides, thiadiazoles, oxadiazoles, biphenyl derivatives, molecular docking.
Current Pharmaceutical Design
Title:Small Molecules as PD-1/PD-L1 Pathway Modulators for Cancer Immunotherapy
Volume: 24 Issue: 41
Author(s): Peifu Jiao, Qiaohong Geng*, Peng Jin, Gaoxing Su, Houyun Teng, Jinlong Dong and Bing Yan*
Affiliation:
- Department of Chemistry, Qilu Normal University, Jinan, Shandong 250013,China
- School of Environmental Science and Engineering, Shandong University, Jinan, Shandong 250100,China
Keywords: Immune checkpoint modulators, sulfonamides, thiadiazoles, oxadiazoles, biphenyl derivatives, molecular docking.
Abstract: Blockade of PD-1/PD-L1 interactions using PD-1/PD-L1 pathway modulators has shown unprecedented clinical efficacy in various cancer models. Current PD-1/PD-L1 modulators approved by FDA are exclusively dominated by therapeutic antibodies. Nevertheless, therapeutic antibodies also exhibit several disadvantages such as low tumor penetration, difficulty in crossing physiological barriers, lacking oral bioavailability, high manufacturing costs, inaccessible to intracellular targets, immunogenicity, immune-related adverse events (irAEs). Modulation of PD-1/PD-L1 pathway using small molecules may be an alternative approach to mobilize immune system to fight against cancers. In this review, we focus on summarizing the recently disclosed chemical structures and preliminary structure-activity relationships (SARs) of small molecules as PD-1/PD-L1 modulators for cancer immunotherapy.
Export Options
About this article
Cite this article as:
Jiao Peifu , Geng Qiaohong *, Jin Peng, Su Gaoxing, Teng Houyun , Dong Jinlong and Yan Bing *, Small Molecules as PD-1/PD-L1 Pathway Modulators for Cancer Immunotherapy, Current Pharmaceutical Design 2018; 24 (41) . https://dx.doi.org/10.2174/1381612824666181112114958
DOI https://dx.doi.org/10.2174/1381612824666181112114958 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical Impact of Gastric Acid Suppressants Use on the Efficacy of Gefitinib in Patients with Advanced Adenocarcinoma of the Lung Harboring Common EGFR Mutations
Clinical Cancer Drugs The Link Between Conventional and Novel Anti-Cancer Therapeutics with Thrombotic Microangiopathy
Drug Metabolism Letters Using the Chou’s Pseudo Component to Predict the ncRNA Locations Based on the Improved K-Nearest Neighbor (iKNN) Classifier
Current Bioinformatics Synthesis and Evaluation of 2-Substituted Fendiline Analogues as Antileukemics
Letters in Drug Design & Discovery Glycolipid Antigen – Mediated Invariant NKT Cell Activation in Microbial Immunity
Current Immunology Reviews (Discontinued) Gene Therapy for Gastric Diseases
Current Gene Therapy PET/CT Based Dose Planning in Radiotherapy
Current Medical Imaging TRICOM Vector Based Cancer Vaccines
Current Pharmaceutical Design Design, Synthesis and Studies on Novel Polymeric Prodrugs of Erlotinib for Colon Drug Delivery
Anti-Cancer Agents in Medicinal Chemistry Computer-aided Diagnosis of Lung Cancer in Computed Tomography Scans: A Review
Current Medical Imaging Alzheimer’s Disease and Molecular Chaperones: Current Knowledge and the Future of Chaperonotherapy
Current Pharmaceutical Design B Cell Modulation Strategies in Autoimmunity: The SLE Example
Current Pharmaceutical Design Maximizing Baculovirus-Mediated Foreign Proteins Expression in Mammalian Cells
Current Gene Therapy Epidemiological Evidence Associating Secondhand Smoke Exposure with Cardiovascular Disease
Inflammation & Allergy - Drug Targets (Discontinued) Cancer Therapy By Targeting Hypoxia-Inducible Factor-1
Current Cancer Drug Targets Dysregulated Chemokine Signaling in Cystic Fibrosis Lung Disease: A Potential Therapeutic Target
Current Drug Targets Towards Human on a Chip: Recent Progress and Future Perspective
Micro and Nanosystems Influence of CYP2D6 Genetics on Opioid Kinetics, Metabolism and Response
Current Pharmacogenomics Predicting Drug Efficacy Using Integrative Models for Chronic Respiratory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Mouse Induced Glioma-Initiating Cell Models and Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry